丹纳赫发布2025年Q2财报：同比增长3.5%，营收超预期

Core Viewpoint - Danaher reported Q2 2025 financial results that exceeded expectations, driven by strong growth in the biotechnology sector, leading to an increase in both revenue and adjusted EPS, and subsequently raised its full-year guidance [1][2]. Revenue Performance - Total revenue for Q2 2025 reached $5.94 billion, representing a year-over-year growth of 3.5%, surpassing analyst expectations of $5.84 billion [3]. - Adjusted EPS was $1.80, a year-over-year increase of 4.7%, exceeding the expected $1.64 [4]. Business Segment Highlights - The biotechnology segment saw an 8% year-over-year sales increase, becoming the primary growth driver, offsetting slowdowns in the life sciences and diagnostics segments [6]. - The life sciences segment experienced a slowdown but benefited from demand in the pharmaceutical and biopharmaceutical sectors [7]. - The diagnostics segment faced weak growth due to market fluctuations, although it partially mitigated declines in other segments [8]. Profit and Cost Control - Cumulative net profit for the year as of June 27, 2025, was $1.509 billion, a decrease of 24.36% year-over-year [9]. - Specific Q2 gross margin data was not disclosed, but overall gross margin performance was impacted by supply chain adjustments and tariffs [9]. Strategic and Market Dynamics - The company announced Matthew Gugino as the new CFO, effective February 28, 2026, indicating management stability and strategic continuity [11]. - In Q2 2025, Danaher repurchased $1.078 billion in stock, reflecting confidence in its valuation [12]. Stock Performance - Following the earnings release on July 23, 2025, Danaher's stock surged 5.45% to $200.255 per share, achieving a market capitalization of $143.393 billion, a record high [14]. - The stock had previously declined by 5.19% in pre-market trading on July 22 due to cautious market expectations, but rebounded sharply after the earnings report [15]. Industry Challenges and Responses - The company is actively addressing cost pressures from tariffs through supply chain optimization, fee adjustments, and manufacturing layout improvements, with an expected core revenue growth of approximately 3% for the year [17]. - In Q2 2024, sales in the Chinese market declined by 7.93%, but Q2 2025 data for China was not separately mentioned, necessitating attention to future quarters for potential recovery [18]. - The diagnostics segment faced pressure from healthcare policy adjustments, such as "volume-based procurement," which led to a 1.5% decline in core revenue in Q1 2025, warranting ongoing monitoring of policy impacts on long-term profitability [19]. Full-Year Outlook - The company anticipates a 3% growth in core revenue for the year, with the biotechnology business expected to outpace the life sciences segment [21]. - Adjusted EPS guidance has been raised to $7.70-$7.80, up from the previous $7.60-$7.75, reflecting confidence in cost control and operational efficiency [5][22]. - Long-term strategy focuses on optimizing productivity through the Danaher Business System (DBS), targeting high-growth areas such as biotechnology and environmental solutions, and pursuing mergers and acquisitions, including collaboration with Ascend Bio for gene editing therapies [22].